2020 Clinical Review: Mindfulness Interventions Reduce Blood Pressure
2019 Preclinical Study: Modified Citrus Pectin Improves Ischemic Heart Failure by Downregulating Galectin 3 and Reducing Myocardial Fibrosis
2019 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Prevent Profibrotic and Proinflammatory Effects of Cardiotrophin-1 (CT-1) in Myocardial Fibrosis
2019 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 and Prevents Cardiac Damage, Inflammation, and Fibrosis Following Kidney Injury
2019 Preclinical Study: Modified Citrus Pectin Blocked Galectin-3 and Reduced the Pro-Inflammatory, Pro-fibrotic, and Pro-osteogenic Response in Aortic valves in Patients Undergoing Aortic Valve Replacement
2019 Preclinical Study: Modified Citrus Pectin Blockade of Galectin-3 Prevents Cardiac Fibrosis, Inflammation and Functional Alterations
2018 Preclinical Study: Modified Citrus Pectin Prevents Blood-Brain Barrier Disruption in Mouse Subarachnoid Hemorrhage by Inhibiting Galectin-3
2018 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 and Protects Against Renal Injury and Fibrosis
2018 Preclinical Study: Modified Citrus Pectin Inhibits Colon Cancer Migration via Galectin-3 Inhibition
2018 Preclinical Study: Modified Citrus Pectin Increases Antioxidant Activity and Reduces Oxidative Stress in Hypertension Model, through Inhibition of Galectin-3
2018 Preclinical Study: Inhibition of Galectin-3 with Modified Citrus Pectin Mitigates Diet-Induced Cardiac Lipotoxicity and Reduces Mitochondrial Damage
2018 Preclinical Study: Inhibition of Galectin-3 with Modified Citrus Pectin Reduces Inflammatory Mediators and Decreases Kidney Damage in Spontaneous Hypertension Model
2017 Preclinical Study: Modified Citrus Pectin Protects Vascular Tissue against Abdominal Aortic Aneurism by Decreasing Galectin-3 and Inflammatory Cytokine Expression
2017 Preclinical Study: Modified Citrus Pectin Reduces Size of Atherosclerotic Lesions, via Inhibition of Galectin-3
2017 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Prevent Cardiac Remodeling, Fibrosis and Inflammation Associated with Early Aortic Stenosis
2017 Preclinical Study: Galectin-3 inhibition with Modified Citrus Pectin Blocks Inflammation, Fibrosis and Calcification in Aortic Valves
2016 Preclinical Study: Modified Citrus Pectin Blocks Inflammation and Fibrosis and Prevents Calcification in Aortic Stenosis, via Inhibition of Galectin-3
2016 Preclinical Study: Modified Citrus Pectin Prevents Adipose (Fat)Tissue Remodeling in Obesity, via Inhibition of Galectin-3
2016 Preclinical Study: Modified Citrus Pectin Prevents Left Ventricle Dysfunction and Cardiac Fibrosis, through Inhibition of Galectin-3
2015 Preclinical Study: Modified Citrus Pectin Prevents Obesity-Related Cardiovascular Remodeling, through Inhibition of Galectin-3
2015 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Inhibit Cardiac Inflammation and Fibrosis in Experimental Hypertension
2015 Preclinical Study: Modified Citrus Pectin Prevents Cardiac and Kidney Fibrosis, via Inhibition of Galectin-3
2013 Preclinical Study: Modified Citrus Pectin Reverses Vascular Hypertrophy and Fibrosis, via Inhibition of Galectin-3
By submitting this form you are agreeing to receive email communications from Dr. Eliaz
